Sains Medisina

Vol. 4, No. 2, Hal. 147-153
Desember 2025
ISSN 2964-1853 (online)
DOI: 10.63004/snsmed.v4i2.885

Overcoming Regulatory Barriers: A Narrative Review of Implementation Strategies and Cultural Challenges of Lean Six Sigma in a GMP Environment

Fhahira Alifiya[1*], Andi Fadilla[2]
[1]*Pharmacist Professional Education Program, Universitas Sari Mulia, Banjarmasin, Indonesia*
[2]*Department of Pharmacy, Sekolah Tinggi Ilmu Kesehatan Samarinda, Samarinda, Indonesia*
*email Korespondensi: alifiyafhahi@gmail.com

ABSTRAK. Industri manufaktur farmasi dituntut untuk mencapai efisiensi operasional tanpa mengabaikan kepatuhan terhadap regulasi Good Manufacturing Practice (GMP). Tuntutan ganda ini sering kali membatasi pelaksanaan perbaikan proses. Lean Six Sigma (LSS) merupakan pendekatan manajemen terstruktur yang mengintegrasikan peningkatan efisiensi dengan kepatuhan regulatori. Artikel ini bertujuan untuk menganalisis strategi implementasi LSS dalam industri farmasi dari perspektif manajemen dan regulasi. Metode yang digunakan adalah telaah pustaka naratif terhadap artikel-artikel terpilih dari basis data ilmiah utama. Karena keterbatasan studi empiris pada lingkungan farmasi yang sangat teregulasi, lima studi kasus yang relevan dianalisis secara reflektif dengan menekankan strategi manajerial, hambatan regulasi, dan budaya organisasi dalam penerapan LSS. Hasil kajian menunjukkan bahwa LSS memperkuat kepatuhan GMP melalui pendekatan berbasis data, khususnya melalui kerangka DMAIC yang mendukung justifikasi perubahan proses. Namun, resistensi budaya dan sikap aversi terhadap risiko masih menjadi tantangan utama. Kesimpulannya, Lean Six Sigma merupakan strategi manajemen yang efektif untuk mengatasi hambatan regulasi dan budaya organisasi serta mendukung keunggulan operasional berkelanjutan tanpa mengorbankan mutu produk.

Kata kunci: Lean Six Sigma, GMP, Manajemen Farmasi, Kepatuhan Regulasi, Keunggulan Operasional

ABSTRACT. *Pharmaceutical manufacturing is required to achieve operational efficiency while strictly complying with Good Manufacturing Practice (GMP) regulations. This dual demand often limits process improvement initiatives. Lean Six Sigma (LSS) provides a structured management approach that integrates efficiency improvement with regulatory compliance. This narrative review analyzes LSS implementation strategies in pharmaceutical manufacturing from a management and regulatory perspective. A focused literature review was conducted using major scientific databases. Due to the limited number of empirical studies conducted in highly regulated GMP environments, five relevant case studies were selected and analyzed using a narrative reflection approach. The analysis focused on managerial strategies, regulatory constraints, and organizational culture influencing LSS implementation. The results show that LSS strengthens GMP compliance by providing data-driven justification for process changes through the DMAIC framework. Lean tools, particularly Value Stream Mapping, enable managers to identify non-value-added activities that are not mandated by regulation. However, cultural resistance and risk-averse organizational behavior remain significant challenges, requiring strong leadership and employee involvement. In conclusion, Lean Six Sigma is an effective management strategy for overcoming regulatory and cultural barriers in pharmaceutical manufacturing while supporting sustainable operational excellence and product quality.*

Keywords: *Lean Six Sigma, GMP, Pharmaceutical Management, Regulatory Compliance, Operational Excellence*

INTRODUCTION

The pharmaceutical manufacturing industry is important to global health, as its core mission is to produce essential and safe medicines, such as tablets, that directly impact consumer well-being. Beyond health, product quality also provides a competitive advantage for the companies themselves (Chatterjee et al., 2005). However, the sector faces a unique and defining challenge: balancing the urgent need for high efficiency and productivity with the absolute requirement for strict quality, safety, and regulatory compliance, primarily enforced through Good Manufacturing Practice (cGMP). This is often described as a paradox between continuous improvement and control. Lean methodologies seek

to achieve speed and innovation by decreasing costs, reducing waste, and improving time-to-market. In stark contrast, the cGMP framework necessitates caution and process stability through rigidly controlled systems to guarantee the product's safety, efficacy, and consistent quality. Therefore, pharmaceutical companies must strategically navigate this inherent conflict, harmonizing efficiency goals with stringent legal regulations to work "smarter" without ever compromising compliance (Chatterjee et al., 2005; Pavlović & Božanić, 2010; Purwanto et al., 2020).

Lean Six Sigma (LSS) is a robust, data-driven methodology that synergizes two distinct improvement philosophies. The Lean component focuses on maximizing efficiency and speed by identifying and eliminating waste (non-value-added activities), thereby achieving goals such as "decreased wait time to release product to the market, reduce production waste". Simultaneously, Six Sigma is a highly disciplined, statistical approach dedicated to improving quality by reducing process variation and defects. ensuring virtually all products meet specifications. LSS integrates these concepts to achieve concurrent improvements in speed and quality. (Pavlović & Božanić, 2010). In the highly regulated pharmaceutical industry, LSS is no longer merely a productivity tool; it is a critical framework for aligning the pursuit of efficiency with mandatory quality and regulatory compliance. It achieves this by providing a systematic approach to reducing process uncertainty, which inherently improves product standards and compliance. The core relevance lies in the "harmonization with legal regulation represented by requirements Good Manufacturing Practice (cGMP), in order to work 'smarter', more cost-effectively and avoid wasting time and other resources". By focusing on defects and waste, LSS acts as a "process improvement strategy used in the pharmaceutical industry to reduce waste, enhance profitability, and enhance product standards", thus embedding quality and compliance into the operational DNA as part of a true Operational Excellence culture (Mahajan et al., 2022).

The primary objective of much of the available literature is to synthesize and analyze successful LSS implementation strategies in pharmaceutical settings, often through focused reviews and case studies, such as the research that "examines a case study on the implementation of an effective approach to advanced Lean". A major focal point is how companies successfully address the unique, internal challenges inherent in the sector. This specifically includes analyzing how organizations overcome cultural challenges the resistance to change often found in cautious, compliance-heavy environments and navigate the restrictive cGMP regulatory barriers to achieve the full efficiency and quality benefits promised by LSS methodologies (Byrne et al., 2021; Haekal, 2021; Singh & Rathi, 2019).

METHOD

The review process utilized a focused, multi-stage selection approach, as detailed in the selection flow diagram above. While the initial search across major databases (Scopus, Google Scholar, etc.) using key terms like 'Lean Six Sigma,' 'Pharmaceutical Manufacturing,' and 'Productivity' yielded a large volume of results (N=244), strict inclusion criteria were applied. This screening process confirmed a critical scarcity of published, empirical case studies specifically detailing LSS implementation within the highly regulated pharmaceutical sector. Consequently, the final evidence base was restricted to five (N=5) highly relevant case studies and quantitative applications. This limitation became a methodological strength, necessitating a 'Narrative Reflection' rather than a wide-ranging systematic aggregation. The important step in this methodology was the re-analysis of the N=5 articles. Recognizing that these articles primarily reported success metrics (e.g., cost savings and productivity gains), we critically re-interpreted their findings. The re-analysis focused exclusively on identifying underlying themes pertinent to our new research focus: Implementation Strategies: How LSS tools (e.g., VSM, DMAIC) were adapted to align with GMP requirements ; Cultural Challenges: Implicit resistance or necessary cultural shifts required for success ; Regulatory Barriers: Specific ways the GMP environment either facilitated or hindered the Improve and Control phases of DMAIC. This re-analysis ensures that the resulting narrative directly addresses the research gap—moving the discourse from *what* LSS achieved to *how* it was strategically

and culturally implemented in a controlled GMP setting—without requiring an extensive and time-consuming search for additional literature.



Figure 1. Flow diagram of the study selection process.

RESULT

The synthesis of the included articles confirms that the successful adoption of Lean Six Sigma (LSS) in pharmaceutical manufacturing is primarily a strategic maneuver to harmonize the inherent tension between regulatory demands and efficiency goals. The core finding is that LSS does not challenge Good Manufacturing Practice (GMP) barriers but rather provides a data-driven framework to make necessary process changes auditable and justifiable. The initial focus of LSS implementation is therefore not just productivity, but the establishment of a statistically defensible case for improvement that satisfies Quality Assurance (QA) requirements, leading to the reported positive and significant effect on overall industry performance (Kartika et al., 2020; Purwanto et al., 2020).This alignment transforms the improvement initiative from a cost-cutting project into a proactive quality management system extension.

The most critical implementation strategy is the use of the DMAIC (Define, Measure, Analyze, Improve, Control) cycle to overcome regulatory rigidity. In the highly regulated environment, any change carries the risk of non-compliance, forcing a cultural aversion to improvement. However, the rigor of the Measure and Analyze phases provides the empirical process capability data (e.g., C_{pk}) necessary to satisfy regulatory bodies that the process is under control and that the change is based on factual root cause analysis (Byrne et al., 2021). Furthermore, the Control phase mandates continuous monitoring and standardized work, which directly supports the GMP requirement for sustained validation and auditable processes, effectively turning LSS into a mechanism for sustained regulatory compliance.

Lean tools, particularly Value Stream Mapping (VSM), are strategically deployed to overcome the regulatory-induced barrier of accepting "compliance waste." In many facilities, excess inventory and prolonged cycle times are mistakenly deemed essential safety buffers against batch failure, perpetuating organizational waste. By applying LSS integrated with VSM (Kholil et al., 2021), organizations successfully identify and isolate waste that is not mandated by regulation, such as high reject rates (3.6% reject rate vs. 0.5% target in one study) or non-value-added waiting time. This methodology provides the visual and statistical proof needed to challenge long-standing, risk-averse practices and implement changes without compromising product quality or regulatory requirements.

The ultimate challenge and key to long-term success lie in cultural transformation. GMP compliance often fosters a culture of rigid adherence and risk aversion, discouraging employees from proactively identifying and solving problems. LSS facilitates the shift from this reactive culture to a proactive, problem-solving culture by empowering personnel through the use of data and statistical tools. The successful application of LSS in various studies implies that management commitment is strong enough to counter initial cultural inertia, reinforcing the idea that efficiency and quality are synergistic. This leads to the formation of a holistic Operational Excellence (OE) culture, which extends beyond simple productivity metrics to include sustainability and ethical considerations (Eskandari et al., 2022).

The research demonstrates that LSS is not merely a method for "Productivity Improvement," but rather the essential implementation strategy for overcoming the dual challenges of regulatory barriers and cultural rigidity in the GMP environment. The methodology's success is a function of its ability to integrate the structured, data-

driven principles of Six Sigma with the waste-reduction principles of Lean, creating changes that are both economically beneficial and statistically defensible the foundation of true Operational Excellence in pharmaceutical manufacturing (Byrne et al., 2021; Kholil et al., 2021).

Table 1. Literature Review Matrix (Summary of Included Studies)

No.	Author(s) & Year	Study Design	Setting	Key Tools	Key Findings
1	Byrne et al. (2021)	Case Study	Pharmaceutical manufacturing facility in Ireland (Blister packaging line).	DMAIC, OEE, 5S, SMED, Fishbone Diagram.	LSS implementation significantly improved Overall Equipment Effectiveness (OEE) and reduced changeover times, moving the process from low average performance to meeting high targets.
2	Kartika et al. (2020)	Quantitative (Survey, n=382 Managers)	Pharmaceutical Industries in Indonesia (Industrial clusters like Cikarang).	Six Sigma phases (Determine, Measure, Improve, Control).	Six Sigma phases have a positive and significant impact on industrial performance. The 'Control' and 'Improve' phases were found to be critical success factors.
3	Purwanto et al. (2020)	Quantitative (Survey, n=300 Managers)	15 Pharmaceutical Industries in Indonesia (5+ years of Six Sigma implementation).	DMIC (Determine, Measure, Improve, Control).	Confirmed that Six Sigma application significantly affects industry performance (Quality & Productivity). The model is valid for predicting performance improvements in the sector.
4	Eskandari et al. (2022)	Integrated Framework (Mixed Method)	Pharmaceutical factory performance evaluation (Case study in Iran).	Lean + Sustainability, DEA, SWOT, Best-Worst Method (BWM).	Proposed a novel framework integrating Lean with Sustainability (Environmental, Social, Economic). Concluded that operational efficiency alone is insufficient without sustainability metrics.
5	Kholil et al. (2021)	Case Study	PT. Medica Indonesia (Tablet coating production line).	DMAIC, VSM (Value Stream Mapping), VALSAT.	Identified critical waste (defects). Successfully reduced the reject rate from a high of 3.6% to below the company's target through process improvements in the coating line.

DISCUSSION

The primary finding across the reviewed literature is that Lean Six Sigma (LSS) is not merely an optional efficiency program in pharmaceutical manufacturing, but a necessary strategic framework for overcoming the fundamental contradiction between the pursuit of competitive efficiency (Lean) and the mandated stability of process control (GMP) (Chatterjee et al., 2005; Purwanto et al., 2020). The quantitative correlation between Six Sigma application and significant performance improvements (Kartika et al., 2020) demonstrates

that LSS provides the auditable structure required to justify change. This success refutes the traditional notion that caution and stability must inherently lead to process stagnation. Instead, LSS provides a formal methodology often referred to as DMIC/DMAIC that re-orients improvement efforts to satisfy both the financial stakeholder (efficiency) and the regulatory stakeholder (compliance), effectively making the business case and the compliance case for change one and the same.

The implementation strategies of LSS succeed in overcoming regulatory barriers by transforming process change from a subjective risk into an objective, data-driven necessity. The Six Sigma (DMAIC) cycle is critical here: the Measure and Analyze phases generate statistical process capability metrics *(C_{pk})* that serve as irrefutable evidence of the need for intervention, circumventing cultural resistance to procedural changes (Byrne et al., 2021). Furthermore, the Lean principle of Value Stream Mapping (VSM) is strategically used to challenge the perceived need for "compliance waste." Case studies show VSM exposing non-value-added activities, such as excessive inventory or defects caused by process variation (Kholil et al., 2021). By providing visual, data-backed proof, VSM allows management to confidently eliminate waste that was previously protected by the organization's risk-averse culture under the guise of safety, thus making efficiency an act of informed risk-mitigation.

The most profound cultural challenge addressed by LSS is the shift from a passive, rule-following mentality to an active, problem-solving one. The GMP environment, by necessity, promotes strict adherence to Standard Operating Procedures (SOPs), which can stifle innovation and create cultural inertia against any change (Mahajan et al., 2022). LSS directly addresses this by empowering Green and Black Belts to use statistical tools to identify the root cause of problems, transforming employees from mere executors of SOPs into owners and improvers of the process. This structural shift in decision-making authority, supported by formal training and project execution, is essential to institutionalize continuous improvement and overcome the fear that change equates to regulatory non-compliance.

Beyond immediate productivity, the LSS model offers a pathway toward a holistic Quality Management System (QMS), directly addressing the future challenges of the pharmaceutical sector. Integrating LSS with concepts like sustainability, which focuses on environmental, social, and economic factors demonstrates that the methodology can evolve beyond the shop floor (Eskandari et al., 2022). This integration reinforces the idea that true Operational Excellence (OE) requires maximizing resource efficiency (Lean) while minimizing variation and defect rates (Six Sigma) across all pillars of corporate responsibility. In the context of regulatory scrutiny, this broad, integrated LSS framework offers comprehensive, data-backed evidence of a high-quality culture, far exceeding the minimum requirements of basic GMP.

In summary, the narrative evidence suggests that LSS is the optimal implementation strategy because its inherent reliance on data and structured phases successfully negotiates the complex relationship between operational dynamism and regulatory conservatism. Future research must shift focus from simply measuring LSS outcomes to analyzing the cultural sustainability of LSS, specifically developing quantitative metrics to measure the longitudinal success of leadership commitment and employee empowerment, particularly in environments prone to bureaucratic resistance. This will be essential for creating the "tomorrow" of pharmaceutical manufacturing: a process that is not only clean and safe, but also reliably fast and efficient.

CONCLUSION

The narrative review decisively concludes that Lean Six Sigma (LSS) functions as the necessary and successful implementation strategy to overcome the primary operational conflict in pharmaceutical manufacturing: the tension between competitive efficiency (Lean) and mandated process stability (GMP). LSS achieves this not by challenging regulatory demands, but by providing a data-driven framework that makes process change auditable and justifiable (Mahajan et al., 2022). Specifically, the DMAIC cycle's rigorous Measure and Analyze phases generate the statistical process capability metrics (Six Sigma) required to satisfy regulatory

bodies that modifications are based on verifiable root causes, thus streamlining the process validation required by GMP (Byrne et al., 2021). Furthermore, Lean tools like Value Stream Mapping (VSM) strategically deconstruct ingrained regulatory waste—non-value-added activities performed out of risk-aversion—by empirically distinguishing necessary compliance from organizational inefficiency, thereby transforming improvement from a perceived risk into a quality-enhancing asset. Crucially, the long-term success of LSS hinges on addressing the persistent cultural challenges posed by the inherently risk-averse GMP environment. The quantitative evidence showing a positive and significant effect of Six Sigma on pharmaceutical industry performance serves as the necessary reinforcement for leadership buy-in and employee commitment. By empowering the workforce with statistical problem-solving tools, LSS transforms the culture from one of rigid adherence to SOPs into one of proactive ownership and continuous improvement. This cultural transformation, coupled with the statistical process control mandated by the DMAIC Control phase, ensures that efficiency gains are sustainable and integrated into the overall Quality Management System (QMS), paving the way for comprehensive Operational Excellence that meets both economic and regulatory goals.

Acknowledgments

Special appreciation is extended to the Pharmacist Professional Education Program, Universitas Sari Mulia, Banjarmasin, Indonesia and the Department of Pharmacy, Sekolah Tinggi Ilmu Kesehatan Samarinda, Samarinda, Indonesia for providing the necessary facilities and supportive academic environment for this research.

REFERENCES

Byrne, B., McDermott, O., & Noonan, J. (2021). Applying lean six sigma methodology to a pharmaceutical manufacturing facility: A case study. *Processes*, *9*(3). https://doi.org/10.3390/pr9030550.

Chatterjee, B., Ruano, B., & Myers, K. (2005). *Six Sigma Principles SEPTEMBER/OCTOBER 2005 PHARMACEUTICAL ENGINEERING 1 Applying Six Sigma Principles to a Bulk and Fill/Finish Biopharmaceutical Process*.

Eskandari, M., Hamid, M., Masoudian, M., & Rabbani, M. (2022). An integrated lean production-sustainability framework for evaluation and improvement of the performance of pharmaceutical factory. *Journal of Cleaner Production*, *376*. https://doi.org/10.1016/j.jclepro.2022.134132 .

Haekal, J. (2021). Application of Lean Six Sigma Approach to Reduce Worker Fatigue in Racking AreasUsing DMAIC, VSM, FMEA and ProModelSimulation Methods in Sub Logistic Companies: A Case Study of Indonesia. *International Journal of Engineering Research and Advanced Technology*, *07*(06), 01–11. https://doi.org/10.31695/ijerat.2021.3716.

Kartika, H., Norita, D., Elisa Triana, N., Roswandi, I., Rahim, A., Naro, A., Izzati, T., Asvaroza Munita, A., Junaedi, D., Suprihatiningsih, W., Purwanto, A., Setia Bakti, C., & Tinggi Teknologi Yupentek, S. (2020). Six Sigma Benefit for Indonesian Pharmaceutical Industries Performance: A Quantitative Methods Approach. In *Systematic Reviews in Pharmacy* (Vol. 11, Issue 9).

Kholil, M., Haekal, J., Suparno, A., Oktaandhini, D. S., & Widodo, T. (2021). Lean Six sigma Integration to Reduce Waste in Tablet coating Production with DMAIC and VSM Approach in Production Lines of Manufacturing Companies. *International Journal Of Scientific Advances*, *2*(5). https://doi.org/10.51542/ijscia.v2i5.8.

Mahajan, S. S., Savita, N., & Kumar, S. (2022). The Important Role of Six Sigma in Pharmaceutical Industry-A Review. *Indian Journal of Health Care*, *3*.

Pavlović, K., & Božanić, V. (2010). *259 Katarina Pavlović 1) Lean and Six Sigma Concepts-Application in Pharmaceutical Industry*. www.pharmafocusasia.com,

Purwanto, A., Mukti Wirawati, S., Ndaru Arthawati, S., Setyo Radyawanto, A., Rusdianto, B., Haris, M., Kartika, H., Rasis Rabathi, S., Fahlevi, M., Zaenal Abidin, R., & Ary Yunanto, D. (2020). Lean Six Sigma Model for Pharmacy Manufacturing: Yesterday, Today and Tomorrow. *Systematic Reviews in Pharmacy*, *11*(8), 304–313.

Singh, M., & Rathi, R. (2019). A structured review of Lean Six Sigma in various industrial sectors. In *International Journal of Lean Six Sigma* (Vol. 10, Issue 2, pp. 622–664).

Emerald Group Holdings Ltd. https://doi.org/10.1108/IJLSS-03-2018-0018.